Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sean Maduck Sells 25,000 Shares
Insider Sean Maduck of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) sold 25,000 shares of the company in a trade on Thursday, November 10. The shares were sold at an average price of $25.57, for a total transaction of $639,250.00. Following the transaction, the insider now directly owns 56,462 shares of the company, valued at $1,443,733.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link.
Sean Maduck also recently made the following trade(s):
- On Monday, October 3, Sean Maduck sold 25,000 shares of Corcept Therapeutics. The shares were sold at an average price of $25.64, for a total transaction of $641,000.00.
Corcept Therapeutics Price Performance
Shares of Corcept Therapeutics rose $0.87 on Tuesday, hitting $26.69. The company had a trading volume of 560,203 shares, compared to an average volume of 772,679. The company has a market capitalization of $2.87 billion, a price/earnings ratio of 26.77, a P/E ratio /G of 2.56 and a beta of 0.56. The company’s 50-day moving average price is $26.58 and its two-hundred-day moving average price is $25.02. Corcept Therapeutics Incorporated has a 1 year minimum of $15.82 and a 1 year maximum of $30.14.
A Wall Street analyst gives his opinion
A number of equity research analysts have recently commented on CORT shares. StockNews.com downgraded Corcept Therapeutics from a “strong buy” rating to a “buy” rating in a research report on Saturday. Truist Financial downgraded shares of Corcept Therapeutics to a “hold” rating in a Tuesday, August 9 report. Jefferies Financial Group upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and raised its price target for the stock from $21.00 to $35.00 in a research report from the Wednesday, July 27. Finally, HC Wainwright raised its price target on Corcept Therapeutics shares from $29.00 to $33.00 and gave the company a “buy” rating in a Thursday, Aug. 4 research report. One investment analyst gave the stock a hold rating and four gave the company’s stock a buy rating. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.
Institutional entries and exits
Institutional investors and hedge funds have recently been buying and selling shares of the company. Gladius Capital Management LP purchased a new stake in shares of Corcept Therapeutics in Q2 worth approximately $31,000. Quadrant Capital Group LLC increased its stake in Corcept Therapeutics by 714.0% during the third quarter. Quadrant Capital Group LLC now owns 1,571 shares of the biotech company valued at $40,000 after buying 1,378 additional shares in the last quarter. Financial Management Professionals Inc. acquired a new stake in Corcept Therapeutics in Q2 worth approximately $47,000. Altshuler Shaham Ltd increased its stake in Corcept Therapeutics by 67.6% in the third quarter. Altshuler Shaham Ltd now owns 2,286 shares of the biotech company worth $58,000 after buying 922 more shares in the last quarter. Finally, Lazard Asset Management LLC increased its position in Corcept Therapeutics shares by 2,286.8% during the second quarter. Lazard Asset Management LLC now owns 2,530 shares of the biotech company valued at $60,000 after purchasing an additional 2,424 shares during the period. 78.46% of the shares are held by hedge funds and other institutional investors.
Corcept Therapeutics Company Profile
(Get an assessment)
Corcept Therapeutics Incorporated discovers, develops and markets drugs for the treatment of serious metabolic, oncological and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not candidates for surgery.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Corcept Therapeutics, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Corcept Therapeutics wasn’t on the list.
Although Corcept Therapeutics currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here